Advertisement

Review of Industrial Organization

, Volume 53, Issue 1, pp 173–210 | Cite as

The Impact of the Entry of Biosimilars: Evidence from Europe

  • Fiona M. Scott Morton
  • Ariel Dora SternEmail author
  • Scott Stern
Article

Abstract

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics from competition. We analyze European markets, which have had biosimilar competition since 2006. Using our own survey, we analyze how market features and public policies predict biosimilar entry, price, and penetration, finding significant heterogeneity across countries and products. Effective buyer institutions are associated with increased biosimilar penetration. Our estimates can inform ongoing policy discussions.

Keywords

Health care Biosimilars Biologics Pharmaceutical competition Health care spending Innovation 

Notes

Acknowledgements

We are grateful to Ernie Berndt, Bill Comanor, Innessa Colaiacovo, James Leung, Robert Meyer, Andrew Mulcahy, Stacy Springs, Robert Town, and seminar participants at Boston University, UCLA, the Kellogg Health Care Markets Conference, Harvard Business School, Harvard Medical School, Tulane University, the University of Virginia, IFS, KU Leuven, ASHEcon, the NBER Productivity Lunch, and the Bates White Life Sciences Symposium for helpful suggestions. Several experts in and well acquainted with the health ministries of European countries in our sample provided valuable information on domestic drug procurement policies. Suzette Kox, Julie Maréchal, Pieter Dylst, and Maarten Van Baelen from Medicines for Europe were particularly generous with their time. Prof. Fernando de Mora in the Department of Pharmacology, Therapeutics and Toxicology at the Universitat Autònoma de Barcelona—Spain provided detailed scientific and regulatory detail. Melissa Ouellet, Oliver Falvey, Lila Kelso, Brittany Ngo, and Kathrin Lampert provided excellent research and editorial assistance. Funding from the National Science Foundation award number 1064341 (The Industrial Organization of the Biologics Industry: theory, Empirics and Policy) and the National Institute on Aging, through grant number T32-AG000186 to the National Bureau of Economic Research, is Gratefully acknowledged. We are particularly appreciative of access to IMS data that was provided by Pfizer Inc. and IMS.

Supplementary material

11151_2018_9630_MOESM1_ESM.pdf (329 kb)
Supplementary material 1 (PDF 328 kb)

References

  1. Acemoglu, D., & Linn, J. (2004). Market size in innovation: Theory and evidence from the pharmaceutical industry. Quarterly Journal of Economics, 3, 1049–1090.CrossRefGoogle Scholar
  2. Averch, H., & Johnson, L. L. (1962). Behavior of the firm under regulatory constraint. American Economic Review, 52(5), 1052–1069.Google Scholar
  3. Berndt, E. R., & Trusheim, M. R. (2015). Biosimilar and biobetter scenarios for the US and Europe: What should we expect? In A. Rosenberg & B. Demeule (Eds.), Biobetters: Protein engineering to approach the curative (pp. 315–360). New York, NY: Springer.CrossRefGoogle Scholar
  4. Berry, S. T. (1992). Estimation of a model of entry in the airline industry. Econometrica, 60, 889–917.CrossRefGoogle Scholar
  5. Bresnahan, T. F., & Reiss, P. C. (1991). Entry and competition in concentrated markets. Journal of Political Economy, 99(5), 977–1009.CrossRefGoogle Scholar
  6. Bulow, J. (2004). The gaming of pharmaceutical patents. Innovation Policy and the Economy, 4, 145–187.CrossRefGoogle Scholar
  7. Cutroneo, P. M., Isgrò, V., Russo, A., Ientile, V., Sottosanti, L., Pimpinella, G., et al. (2014). Safety profile of biological medicines as compared with non-biologicals: An analysis of initial spontaneous reporting system database. Drug Safety, 37, 961–970.CrossRefGoogle Scholar
  8. Danzon, P. M., & Chao, L.-W. (2000). Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics, 43(2), 311–358.CrossRefGoogle Scholar
  9. DiMasi, J. A., & Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics, 28(4–5), 469–479.CrossRefGoogle Scholar
  10. Dubois, P., de Mouzon, O., Scott Morton, F. M., & Seabright, P. (2015). Market size and pharmaceutical innovation. RAND Journal of Economics, 46(4), 844–871.CrossRefGoogle Scholar
  11. Duggan, M., & Scott Morton, F. M. (2010). The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review, 100(1), 590–607.CrossRefGoogle Scholar
  12. FDA. (2017). Considerations in demonstrating interchangeability with a reference product; Draft Guidance”. Food and Drug Administration.Google Scholar
  13. Ganslandt, M., & Maskus, K. E. (2004). Parallel imports and the pricing of pharmaceutical products: Evidence from the European Union. Journal of Health Economics, 23(5), 1035–1057.CrossRefGoogle Scholar
  14. Generics and Biosimilars Initiative (GABI). (2015). No relevant difference in ADRs from biosimilars and originators. http://gabionline.net/Biosimilars/Research/No-relevant-difference-in-ADRs-from-biosimilars-and-originators. Accessed 26 February 2018.
  15. Grabowski, H. (2008). Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery, 7(6), 479–488.CrossRefGoogle Scholar
  16. Grabowski, H., Cockburn, I., & Long, G. (2006). The market for follow-on biologics: How will it evolve? Health Affairs, 25(5), 1291–1301.CrossRefGoogle Scholar
  17. Grabowski, H. G., Ridley, D. B., & Schulman, K. A. (2007). Entry and competition in generic biologics. Managerial and Decision Economics, 28(4–5), 439–451.CrossRefGoogle Scholar
  18. Grabowski, H., & Vernon, J. (1986). Longer patents for lower imitation barriers: The 1984 Drug Act. American Economic Review, 76(2), 195–198.Google Scholar
  19. Hamburg, M. A. (2014). Celebrating 30 years of easier access to cost-saving generic drugs. FDA Voice. http://blogs.fda.gov/fdavoice/index.php/2014/09/celebrating-30-years-of-easier-access-to-cost-saving-generic-drugs. Accessed 26 February 2018.
  20. Inderst, R., & Valletti, T. (2009). Price discrimination in input markets. RAND Journal of Economics, 40(1), 1–19.CrossRefGoogle Scholar
  21. Kozlowski, S., Woodcock, J., Midthun, K., & Sherman, R. B. (2011). Developing the nation’s biosimilars program. New England Journal of Medicine, 365(5), 385–388.CrossRefGoogle Scholar
  22. Kyle, M. K. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1), 88–99.CrossRefGoogle Scholar
  23. Laffont, J.-J., & Tirole, J. (1993). A theory of incentives in procurement and regulation. Boston: MIT Press.Google Scholar
  24. MacNeil, J. S., & Douglas, F. (2007). Challenges to establishing a regulatory framework for approving follow-on biologics: A background paper. MIT Center for Biological Innovation. http://cbi.mit.edu/wp-content/uploads/2011/04/FOB_macneil.pdf. Accessed 26 February 2018.
  25. Reiffen, D., & Ward, M. R. (2005). Generic drug industry dynamics. Review of Economics and Statistics, 87(1), 37–49.CrossRefGoogle Scholar
  26. Rovira, J., Espin, J., Garcia, L., & Olry de Labry, A. (2011). The impact of biosimilars’ entry in the EU Market. Granada: Andalusian School of Public Health.Google Scholar
  27. Sarpatwari, A., Avorn, J., & Kesselheim, A. S. (2015). Progress and hurdles for follow-on biologics. New England Journal of Medicine, 372(25), 2380–2382.CrossRefGoogle Scholar
  28. Scott Morton, F. M. (1999). Entry decisions in the generic pharmaceutical industry. The RAND Journal of Economics, 30(3), 421–440.CrossRefGoogle Scholar
  29. Scott Morton, F. M. (2000). Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization, 18(7), 1085–1104.CrossRefGoogle Scholar
  30. Vermeer, N. (2012). Traceability of biopharmaceuticals in spontaneous reporting systems. European Medicines Agency, presentation. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/05/WC500127934.pdf. Accessed 26 February 2018.
  31. Vermeer, N. S., Straus, S. M., Mantel-Teeuwisse, A. K., Domergue, F., Egberts, T. C., Leufkens, H. G., et al. (2013). Traceability of biopharmaceuticals in spontaneous reporting systems: A cross-sectional study in the FDA adverse event reporting system (FAERS) and EudraVigilance databases. Drug Safety, 36, 617–625.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Fiona M. Scott Morton
    • 1
  • Ariel Dora Stern
    • 2
    Email author
  • Scott Stern
    • 3
  1. 1.Yale School of ManagementNew HavenUSA
  2. 2.Harvard Business SchoolBostonUSA
  3. 3.Massachusetts Institute of TechnologyCambridgeUSA

Personalised recommendations